GC Genome Presents AI-Based Liquid Biopsy Poster at AACR

Published 15 Apr.2022 09:47(KST)

[Asia Economy Reporter Chunhee Lee] GC Genome announced on the 15th that it participated in the American Association for Cancer Research (AACR) Annual Meeting held in New Orleans, USA, from the 8th to the 13th (local time), presenting a poster on AI-based liquid biopsy capable of predicting the presence and types of various cancers.

The presentation at this conference was led by Eunhae Cho, head of the GC Genome Research Institute, under the theme "Deep learning algorithm for multi-cancer detection and classification using cf-WGS," introducing a test applying GC Genome's proprietary technology.

This test is designed to detect the presence of nine major cancers (▲lung cancer ▲colorectal cancer ▲breast cancer ▲liver cancer ▲pancreatic cancer ▲bile duct cancer ▲head and neck cancer ▲ovarian cancer ▲esophageal cancer) through whole genome sequencing (WGS) of cell-free DNA circulating in the blood. Additionally, a 'multi-cancer prediction' model is included, enabling prediction of the tissue of origin for six specific cancers (▲lung cancer ▲breast cancer ▲liver cancer ▲pancreatic cancer ▲ovarian cancer ▲esophageal cancer).

In particular, by utilizing deep learning-based AI trained on genomic patterns characteristic of cancer patient groups, it detects abnormal cancer patterns more sensitively than existing liquid biopsies. The company explained that obtaining various information about cancer with a simple blood draw could greatly aid in improving treatment methods for cancer patients.

Director Cho said, "I am pleased to introduce GC Genome's proprietary AI-based liquid biopsy test at AACR," adding, "This technology not only determines the presence of cancer and identifies the tissue of origin but also achieves high performance with over 85% sensitivity at 95% specificity."